Laser chemotherapy of human carcinoma cells with three new anticancer drugs.
A new experimental therapy for squamous carcinoma was tested by sensitizing human tumor cells with light-sensitive anticancer drugs followed by laser illumination at visible or infrared wavelengths. The anthrapyrazole DUP-941 and the isoquinoline derivative DUP-840 were compared with the dianthraquinone hypericin. P3 human squamous carcinoma cells were incubated for 2 h with the drugs at escalating doses ranging from 5 to 100 micrograms/ml, then exposed to visible green 532-nm or infrared 1064-nm light at 300 J output from a KTP/Nd:YAG laser. Tumor cell toxicity measured by in vitro MTT viability assays was minimal after DUP-840 uptake but was slightly enhanced by infrared laser emissions. By contrast, the strong tumoricidal effects seen after DUP-941 uptake were amplified over 10-fold by 532-nm light and up to 2-fold by 1064-nm light. Hypericin-sensitized tumor cells were killed after 532 nm irradiation even at the lowest drug dose but were not affected by 1064-nm illumination. The results suggest that laser chemotherapy with drugs sensitive to photothermal energy could become a useful new treatment modality for cancer.
Eshraghi
A A
AA
Department of Head and Neck Surgery, Groupe Hospitalier Pitie-Salpetriere, Paris, France.
Castro
D J
DJ
Paiva
M B
MB
Graeber
I P
IP
Jongewaard
N
N
Arshadnia
S
S
Lamas
G
G
Soudant
J
J
Saxton
R E
RE
D000873:Anthracenes; D000880:Anthraquinones / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000528:radiation effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D053685:Laser Therapy; D009354:Neodymium; D010569:Perylene / Q000031:analogs & derivatives / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D010710:Phosphates; D010778:Photochemotherapy / Q000379:methods*; D011720:Pyrazoles / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D047069:Pyrazolones; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology* / Q000528:radiation effects / Q000627:therapeutic use; D014025:Titanium; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000528:radiation effects
D000873:Anthracenes; D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; C110426:DUP 840; D007546:Isoquinolines; D010710:Phosphates; D011720:Pyrazoles; D047069:Pyrazolones; D011838:Radiation-Sensitizing Agents; C064806:potassium titanylphosphate; D009354:Neodymium; C050637:losoxantrone; D010569:Perylene; C004965:hypericin; D014025:Titanium